

UNAUDITED INTERIM FINANCIAL STATEMENTS ANNOUNCEMENT FOR THE 3 MONTHS FINANCIAL PERIOD ENDED 31 MARCH ("1Q FY") 2023

This announcement has been prepared by Biolidics Limited (the "**Company**", and together with its subsidiaries, the "**Group**") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist ("**Catalist Rules**"). This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khia, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

TABLE OF CONTENTS

	Page
A: Interim consolidated statements of profit or loss and other comprehensive income	2
B: Statements of financial position	3
C: Consolidated statements of cash flows	4
D: Statements of changes in equity	5
E: Selected notes to the financial statements	7
F: Other information required under the Catalist Rules	23

A. INTERIM CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		Group		
	Note	1Q FY2023 S\$'000	1Q FY2022 S\$'000	+/(-) %
Revenue	4	1,084	464	133.6
Other income	5	15	123	(87.8)
Changes in inventories		152	(84)	n.m.
Purchases		(656)	(268)	144.8
Employee benefits expense	6	(478)	(629)	(24.0)
Depreciation expense	8	(97)	(220)	(55.9)
Amortisation expense	8	-	(104)	(100.0)
Research and development expense	8	(2)	(99)	(98.0)
Other expenses	8	(325)	(350)	(7.1)
Finance costs	7	(36)	(46)	(21.7)
Loss before tax	8	(343)	(1,213)	(71.1)
Income tax credit	9	-	14	(100.0)
Loss for the period		(343)	(1,199)	(71.4)
Other comprehensive loss for the period:				
<i>Items that may be reclassified subsequently to profit or loss</i>				
Effects of translation of foreign operations		-	(54)	(100.0)
Total comprehensive loss for the period		(343)	(1,253)	(72.6)
Loss per share (cents)				
- Basic		(0.07)	(0.45)	
- Diluted		(0.07)	(0.45)	

n.m. – not meaningful

B. STATEMENTS OF FINANCIAL POSITION

		Group		Company	
	Note	As at 31/3/23 S\$'000	As at 31/12/22 S\$'000	As at 31/3/23 S\$'000	As at 31/12/22 S\$'000
Non-current assets					
Plant and equipment	11	16	61	-	1
Right-of-use assets	12	125	107	83	35
		141	168	83	36
Current assets					
Cash and cash equivalents		3,830	5,029	3,517	4,960
Trade receivables		417	515	17	48
Prepayments		176	182	153	168
Other receivables		57	167	664	567
Inventories	15	187	27	-	-
		4,667	5,920	4,351	5,743
Total assets		4,808	6,088	4,434	5,779
Current liabilities					
Trade payables		206	93	6	4
Other payables		626	1,211	567	1,125
Contract liabilities		96	200	96	200
Lease liabilities	16	220	210	157	117
Borrowings	16	1,057	1,050	1,057	1,050
Deferred consideration	17	2,112	3,244	2,112	3,244
		4,317	6,008	3,995	5,740
Net current assets/ (liabilities)		350	(88)	356	3
Non-current liabilities					
Lease liabilities	16	46	60	46	60
Borrowings	16	1,426	1,693	1,426	1,693
Provision for reinstatement cost		15	15	5	5
		1,487	1,768	1,477	1,758
Total liabilities		5,804	7,776	5,472	7,498
Net liabilities		(996)	(1,688)	(1,038)	(1,719)
Equity attributable to owners of the Company					
Share capital	19	65,393	64,358	65,393	64,358
Foreign currency translation reserve		13	13	-	-
Accumulated losses		(66,402)	(66,059)	(66,431)	(66,077)
Total equity		(996)	(1,688)	(1,038)	(1,719)

C. CONSOLIDATED STATEMENTS OF CASH FLOWS

	1Q FY2023 S\$'000	Group 1Q FY2022 S\$'000
Operating activities		
Loss before income tax	(343)	(1,213)
Adjustments for:		
Amortisation expense	-	104
Depreciation of plant and equipment	45	128
Depreciation of right-of-use assets	52	92
Inventories written off	3	18
Writeback of allowance for inventories	(7)	(68)
Loss from remeasurement of deferred consideration	14	-
Loss on disposal of plant and equipment	-	6
Interest expense on lease liabilities	3	5
Interest expense on borrowings	18	26
Accretion of interest on deferred consideration	15	15
Interest income from fixed deposits	(3)	-
Operating cash flows before movement in working capital	(203)	(887)
Trade receivables	98	(21)
Prepayments	5	(93)
Other receivables	110	140
Inventories (Note A)	(156)	44
Trade payables	112	(55)
Other payables	(159)	(131)
Contract liabilities	(104)	(2)
Cash flows used in operations	(297)	(1,005)
Interest received	3	-
Interest paid	(21)	(31)
Net cash used in operating activities	(315)	(1,036)
Investing activities		
Additions to plant and equipment (Note A)	-	(12)
Additions to intangible assets	-	(21)
Partial payment of deferred consideration	(550)	-
Net cash used in investing activities	(550)	(33)
Financing activities		
Payment of principal portion of borrowings	(260)	(253)
Payment of principal portion of lease liabilities	(74)	(69)
Net cash used in financing activities	(334)	(322)
Net decrease in cash and cash equivalents	(1,199)	(1,391)
Cash and cash equivalents at beginning of the period	5,029	3,960
Exchange effects on cash and cash equivalents	-	(69)
Cash and cash equivalents at end of the period	3,830	2,500

Note A: During 1Q FY2022 and 1Q FY2023, the Group transferred inventories to plant and equipment that were loaned out to collaboration partners and customers: -

	1Q FY2023 S\$'000	1Q FY2022 S\$'000
Transfer of inventories to plant and equipment	-	14

D. STATEMENTS OF CHANGES IN EQUITY

(In S\$'000)

	Share capital	Foreign currency translation reserve	Share-based payment reserve	Accumulated losses	Total equity
Group					
Balance as at 1 January 2023	64,358	13	-	(66,059)	(1,688)
<u>Total comprehensive loss for the period</u>					
Loss for the period	-	-	-	(343)	(343)
Other comprehensive loss for the period	-	-	-	-	-
Total	-	-	-	(343)	(343)
<u>Transactions with owners, recognised directly in equity</u>					
Issue of new shares	611	-	-	-	611
Employee share-based payment – equity settled	-	-	424	-	424
Reclassification upon issuance of shares	424	-	(424)	-	-
Total	1,035	-	-	-	1,035
Balance as at 31 March 2023	65,393	13	-	(66,402)	(996)
Balance as at 1 January 2022	58,883	68	67	(56,686)	2,332
<u>Total comprehensive loss for the period</u>					
Loss for the period	-	-	-	(1,199)	(1,199)
Other comprehensive loss for the period	-	(69)	-	-	(69)
Total	-	(69)	-	(1,199)	(1,268)
<u>Transactions with owners, recognised directly in equity</u>					
	-	-	-	-	-
Balance as at 31 March 2022	58,883	(1)	67	(57,885)	1,064

D. STATEMENTS OF CHANGES IN EQUITY (cont'd)

(In S\$'000)	Share capital	Share-based payment reserve	Accumulated losses	Total equity
Company				
Balance as at 1 January 2023	64,358	-	(66,077)	(1,719)
Loss for the period, representing total comprehensive loss for the period	-	-	(354)	(354)
Total	-	-	(354)	(354)
<u>Transactions with owners, recognised directly in equity</u>				
Issue of new shares	611	-	-	611
Employee share-based payment – equity settled	-	424	-	424
Reclassification upon issuance of shares	424	(424)	-	-
Total	1,035	-	-	1,035
Balance as at 31 March 2023	65,393	-	(66,431)	(1,038)
Balance as at 1 January 2022	58,883	67	(54,920)	4,030
Loss for the period, representing total comprehensive loss for the period	-	-	(722)	(722)
Total	-	-	(722)	(722)
Transactions with owners, recognised directly in equity	-	-	-	-
Balance as at 31 March 2022	58,883	67	(55,642)	3,308

E. SELECTED NOTES TO THE FINANCIAL STATEMENTS

1. Corporate information

Biolidics Limited (Registration No. 200913076M) is a limited liability company incorporated and domiciled in Singapore. The Company is listed on the Catalist of SGX-ST.

The condensed interim financial statements for 1Q FY2023 comprise the Company and its subsidiaries (collectively, the “**Group**”).

The principal activities of the Group and the Company are those relating to:

- (a) technology development, technology transfer, marketing, sale and distribution of biomedical technology, life and medicine science related products and services;
- (b) provision of laboratory services; and
- (c) investment holding.

2. Basis of preparation

The condensed interim financial statements for 1Q FY2023 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last audited financial statements for the year ended 31 December 2022 (“**FY2022**”).

The condensed interim financial statements are presented in Singapore Dollars which is the Company’s functional currency. All financial information presented in Singapore Dollars have been rounded to the nearest thousand, unless otherwise stated.

Material Uncertainty Related to Going Concern

The Group had recorded a net loss of approximately S\$0.34 million and a net operating cash outflow of approximately S\$0.32 million for 1Q FY2023. As at 31 March 2023, the Group and the Company was in a net equity deficit position of approximately S\$1.00 million and S\$1.04 million respectively. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern.

To improve the financial health and working capital position of the Group, the Company had completed a renounceable non-underwritten rights issue of new ordinary shares in the issued share capital of the Company (“**Rights Shares**”) in December 2022 (“**Rights Issue**”) pursuant to which the Company raised gross proceeds of approximately S\$5.70 million, before deduction of expenses of approximately S\$0.22 million that was capitalised against the share capital of the Company.

In addition, the Company had on 28 February 2023, entered into a partial settlement deed (“**Partial Settlement Deed**”) with Clearbridge BSA Pte Ltd (“**CBSA**”) to partially settle approximately S\$1.16 million (“**Partial Settlement Sum**”) of the deferred consideration (“**Deferred Consideration**”) (Note 17) owing by the Company to CBSA in connection with the purchase of the entire issued and paid-up share capital of Biomedics Laboratory Pte. Ltd., of which S\$0.55 million of the Partial Settlement Sum (“**Cash Settlement**”).

Sum") will be settled by way of cash and approximately S\$0.61 million of the Partial Settlement Sum satisfied by way of issuance of 37,500,000 new ordinary shares in the issued share capital of the Company ("**Consideration Shares**") at an issue price of S\$0.0163 for each Consideration Share to CBSA. The payment of the Cash Settlement Sum and the issuance of the Consideration Shares to CBSA were completed on 20 March 2023.

As at 31 March 2023, the Group had cash and cash equivalents of approximately S\$3.83 million and was in a positive working capital position of approximately S\$0.35 million.

To support that the financial statements of the Group have been prepared on a going concern basis and to ensure the adequacy of funds required to meet its obligations, working capital and capital commitment needs, the Group has prepared a consolidated cash flow forecast for a 12-month period from 1 May 2023 to 30 April 2024 ("**Cash Flow Forecast**"). In preparing the Cash Flow Forecast, management has taken the following into consideration:

- the challenges faced by the cancer business during the COVID-19 pandemic and the impact of the emergence of competing and newer technologies on the sales of COVID-19 related products in the infectious diseases business;
- the forecasted cash flow from the laboratory services business which is mainly dependent on the projected sales of its SARS-CoV-2 polymerase chain reaction ("**PCR**") testing for COVID-19 and new revenue stream from other testing services; and
- the cost cutting measures that the Group has put in place to manage costs.

After taking into consideration the Cash Flow Forecast, the board of directors of the Company ("**Board**") is of the opinion that the Group and the Company will be able to operate as a going concern and that the use of the going concern assumption in the preparation of the consolidated financial statements of the Group for 1Q FY2023 is appropriate.

Due to the rapidly evolving nature of the COVID-19 pandemic, the demand for COVID-19 PCR tests continues to be exposed to various uncertainties and challenges such as the emergence of competing and newer technologies, product regulatory changes, and changes in travel policies and restrictions. The Group is closely monitoring the developments of the situation and the impact on its COVID-19 PCR testing services.

The Group will continue to explore merger and acquisition opportunities to improve its financial position and performance and may explore opportunities to monetise its assets, as well as fundraising opportunities, including undertaking further equity issuances. The Group remains in discussions with CBSA to explore the settlement options for the remaining amount of the Deferred Consideration and may propose further issuance of new ordinary shares in the issued share capital of the Company to CBSA as settlement of such amount in full or in part.

If the going concern assumption is no longer appropriate, adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which may differ significantly from the amounts at which they are currently recorded in the statements of financial position. In addition, the Group and the Company may have to reclassify non-current assets and liabilities as current assets and liabilities, respectively. Such adjustments have not been made to these financial statements.

2.1 New and amended standards adopted by the Group

The Group has applied the same accounting policies and methods of computation in the preparation of the condensed interim financial statements for 1Q FY2023 as compared to those applied in the audited financial statements for FY2022 except for the adoption of new or revised SFRS(I) and Interpretations of Singapore Financial Reporting Standards ("**SFRS(I) INT**") that are mandatory for financial years beginning on or after 1 January 2023. The Group has adopted all applicable SFRS(I) and SFRS(I) INT that are mandatory for financial years beginning on or after 1 January 2023. The adoption of these SFRS(I) and SFRS(I) INT has no significant impact on the Group's consolidated financial statements.

2.2 Use of judgements and estimates

The preparation of the Group's consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited financial statements for FY2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is as follows:

- Identification of a cash-generating unit ("**CGU**") - Management identified the Group's cancer business and laboratory services business as the 2 CGUs in the Group, having considered the products and services being sold by the Group and the inter-dependency of the cashflows arising from the products and services provided within a CGU.

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

- Expected credit losses ("**ECLs**")

The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns. The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated and changes in the forward-looking estimates are analysed. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the

future. As at 31 March 2023, the carrying amount of the Group's trade receivables was approximately S\$0.42 million (31 December 2022: S\$0.52 million).

In determining the loss allowance for amount due from subsidiaries, when measuring ECL, loss given default constitutes a key input in measuring ECL. Loss given default is an estimate of the loss arising on default. It is based on the difference between the contractual cash flows due and those that the lender would expect to receive. As at 31 March 2023, the carrying amount of the Company's receivables due from subsidiaries was approximately S\$0.63 million (31 December 2022: S\$0.42 million).

- Impairment assessment of plant and equipment and right-of-use assets

Management has carried out a review and determined that there are indicators of impairment for the Group's plant and equipment and right-of-use assets. These assets belong to the Group's Cancer and Laboratory Services CGUs that also form the respective operating segments. The Group determines the recoverable amount of the assets of the Cancer and Laboratory Services CGUs based on the higher of value-in-use and fair value less cost of disposals. The recoverable amount of these assets as at 31 December 2022 have been determined based on their fair value less cost of disposal. The fair value less cost of disposal of the CGUs' assets as at 31 December 2022 have been estimated by management, with the assistance of external valuers and are categorised in Level 3 of the fair value hierarchy. The valuation techniques, key assumptions and inputs are provided in the table below and the sources of information include the financial forecasts prepared by management, historical information and external data. Significant judgement has been applied by management in determining the adjustment for economic obsolescence. The Group concluded that no impairment loss is to be recognised in 1Q FY2023.

- Impairment assessment of investment in subsidiaries

Management has carried out a review and determined that there are indicators of impairment of the Company's investments in subsidiaries. The recoverable amount of the investments as at 31 December 2022 has been estimated based on fair value less cost of disposal (2021: value-in-use) of the relevant CGU's assets as disclosed in Note 3.2(b) above with adjustments to arrive at equity value of the investments. As at 31 March 2023, the carrying amount of the Company's investment in subsidiaries was Nil (31 December 2022: Nil).

3. Seasonal operations

The Group's businesses were not affected significantly by seasonal or cyclical factors during the financial period.

4. Revenue

The Group derives its revenue from the transfer of goods and services over time and at a point in time in the following major revenue streams. This is consistent with the revenue information that is disclosed for each reportable segment under SFRS(I) 8 (see Note 23).

Disaggregation of revenue

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Sale of COVID-19 products	-	334
Sale of devices and consumables	96	37
Sale of extended warranty services	12	25
Rendering of laboratory services	976	68
	1,084	464
Timing of transfer of goods or services		
At point in time	1,072	439
Over time	12	25
	1,084	464

5. Other income

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Government grants	26	14
Foreign exchange gain, net	-	109
Loss from remeasurement of deferred consideration	(14)	-
Others	3	-
	15	123

6. Employee benefits expense

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Directors' remuneration	59	57
Salaries and bonuses	460	509
Employer's contribution to defined contribution plans	55	63
Reversal of provision for performance bonus	(96)	-
	478	629

7. Finance costs

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Interest expense on borrowings	18	26
Interest expense on lease liabilities	3	5
Accretion of interest on deferred consideration	15	15
	<u>36</u>	<u>46</u>

8. Loss before tax

The following items have been included in arriving at loss before tax:

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Amortisation of intangible assets	-	104
Depreciation of plant and equipment	45	128
Depreciation of right-of-use assets	52	92
Loss on disposal of plant and equipment	-	6
Inventories written off	3	18
Provision for unconsumed leave	-	21
Rental expenses	1	3
Travelling expenses	3	12
Professional fees (cash-settled)	94	77
Sales and marketing expenses	6	10
Repairs and maintenance	8	15
Staff training	-	1
Delivery charges	-	9

Research and development expense

Research and development expense are incurred for product and service development, research collaboration and testing purposes.

9. Income tax credit

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Current income tax	-	-
Deferred income tax		
- Origination and reversal of temporary differences	-	(14)
Income tax credit recognised in profit or loss	-	(14)

10. Loss per share

Basic loss per share is calculated by dividing loss for the period, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period.

Diluted loss per share is calculated by dividing loss for the period, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.

	Group	
	1Q FY2023	1Q FY2022
Loss for the period, net of tax, attributable to owners of the Company used in the computations of basic and diluted loss per share (S\$'000)	(343)	(1,199)
Weighted average number of shares for (basic and diluted) loss per share computation ('000)	505,910	265,047
Basic loss per share (cents)	(0.07)	(0.45)
Diluted loss per share (cents)	(0.07)	(0.45)

11. Plant and equipment

During 1Q FY2023, the Group acquired plant and equipment amounting to Nil (1Q FY2022: S\$12,000) and transferred inventories amounting to Nil (1Q FY2022: S\$14,000), that were loaned out to collaboration partners and customers, to plant and equipment.

Impairment assessment of plant and equipment

The Group has carried out impairment assessment for plant and equipment by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment and right-of-use assets. Based on the impairment assessment, no impairment charge was required as at 31 March 2023.

12. Right-of-use assets

The Group has lease contracts for office and warehouse premises, laboratory space, and office and laboratory equipment used in its operations. Leases of office premise, laboratory space and warehouse premise generally have lease terms of 1 year or less, while office and laboratory equipment generally have lease terms of 3 to 5 years. The Group's obligations under its leases are secured by the lessor's title to the leased assets. Generally, the Group is restricted from assigning and subleasing the leased assets. There are no lease contracts that include extension or termination options and variable lease payments.

There were additions of right-of-use assets of S\$70,000 during 1Q FY2023 (1Q FY2022: Nil).

Impairment assessment of right-of-use assets

The Group has carried out impairment assessment for right-of-use assets by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment, intangible assets and right-of-use assets. Based on the impairment assessment, no impairment charge was required as at 31 March 2023.

13. Intangible assets

Group	Accreditation S\$'000	Patent rights S\$'000	Trademark S\$'000	Total S\$'000
Cost:				
At 31 December 2022 and 31 March 2023	3,329	913	92	4,334
Accumulated amortisation and impairment:				
At 31 December 2022 and 31 March 2023	3,329	913	92	4,334
Carrying amount:				
At 31 December 2022 and 31 March 2023	-	-	-	-

Company	Patent rights S\$'000	Trademark S\$'000	Total S\$'000
Cost:			
At 31 December 2022 and 31 March 2023	913	92	1,005
Accumulated amortisation and impairment:			
At 31 December 2022 and 31 March 2023	913	92	1,005
Carrying amount:			
At 31 December 2022 and 31 March 2023	-	-	-

Impairment assessment of intangible assets

The Group has carried out impairment assessment for intangible assets by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment, intangible assets and right-of-use assets. Based on the impairment assessment, no impairment charge was required as at 31 March 2023.

14. Goodwill

Goodwill arising from the acquisition of Biomedics Laboratory Pte. Ltd. represents the excess over fair value of assets and liabilities acquired.

Impairment assessment of goodwill

Goodwill that has an indefinite useful life is not subject to amortisation and is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired. The Group has carried out impairment assessment for goodwill by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E – Selected notes to the financial statements of this announcement. Based on the impairment assessment, no impairment charge was required as at 31 March 2023.

15. Inventories

	Group		Company	
	As at 31/3/23	As at 31/12/22	As at 31/3/23	As at 31/12/22
	S\$'000	S\$'000	S\$'000	S\$'000
Balance sheet:				
Finished goods	187	27	-	-
	187	27	-	-

	Group	
	1Q FY2023	1Q FY2022
	S\$'000	S\$'000
Income statement:		
Inventories recognised as an expense in cost of sales	504	352
Inventories recognised as an expense in other expenses		
- Inventories written off	3	18

16. Loans classified as lease liabilities and borrowings

	Group		Company	
	As at 31/3/23	As at 31/12/22	As at 31/3/23	As at 31/12/22
	S\$'000	S\$'000	S\$'000	S\$'000
Amount repayable within one year or on demand				
Secured (Note A)	101	116	80	79
Unsecured	1,057	1,050	1,057	1,050
Amount repayable after one year:				
Secured (Note A)	40	60	40	60
Unsecured	1,426	1,693	1,426	1,693

Note A: Assets pledged as security

The Group's hire purchase loans classified as lease liabilities, which amounted to S\$141,000 as at 31 March 2023 (31 December 2022: S\$120,000), are secured as collateral against the Group's right-of-use assets which have a net carrying amount of Nil as at 31 March 2023 (31 December 2022: Nil).

17. Deferred consideration

The Company had on 28 February 2023 entered into the Partial Settlement Deed with CBSA to partially settle S\$1,161,250 of the Deferred Consideration, of which S\$550,000 of the Partial Settlement Sum was settled by way of cash and the remaining S\$611,250 was satisfied by way of issuance of 37,500,000 Consideration Shares. The payment of the Cash Settlement Sum and the issuance of the Consideration Shares to CBSA were completed on 20 March 2023.

The movement of the Deferred Consideration during the period was as follows:

	Group and Company
	S\$'000
Balance as at 1 January 2023	3,244
Repayment of Partial Settlement Sum	(1,161)
Loss on remeasurement	14
Accreditation of interest	15
Balance as at 31 March 2023	2,112

18. Deferred tax liabilities

Deferred tax liabilities of the Group arose from fair value adjustment on acquisition of subsidiary:

	Group 1Q FY2023 S\$'000	1Q FY2022 S\$'000
Balance as at 1 January	-	476
Reversal to profit and loss (See Note 9)	-	(14)
Balance as at 31 March	-	462

19. Share capital

	Number of shares	Share capital S\$'000
As at 31 December 2022	493,367,905	64,358
Issuance of new shares (" Shares ") pursuant to vesting of awards (" Awards ") granted under the Biolidics Performance Share Plan (" Plan ")	28,258,700	424
Issuance of Consideration Shares	37,500,000	611
As at 31 March 2023	559,126,605	65,393

On 1 March 2023, the Company allotted and issued an aggregate of 28,258,700 new Shares to certain employees and a director of the Company pursuant to the vesting of Awards granted under the Plan. On 20 March 2023, the Company allotted and issued the 37,500,000 Consideration Shares to CBSA pursuant to the Partial Settlement Deed.

As at 31 March 2022, the Company had no outstanding convertibles.

As at 31 March 2023, the Company had up to 42,159,600 new Shares ("**Award Shares**") to be issued to certain employees and a director of the Company subject to the vesting of outstanding Awards granted under the Plan upon the achievement of predetermined performance targets, of which (a) up to 21,079,800 Awards will vest within 2 months from 1 March 2023, and (b) up to 21,079,800 Awards will vest within 4 months from 1 January 2024. The outstanding 42,159,600 Award Shares represent approximately 7.54% of the total number of issued Shares (excluding treasury shares) as at 31 March 2023.

Summarised information regarding the number of Award Shares as at 31 March 2023 is as follows:

	As at the beginning of the financial period	Granted during the financial period	Vested during the financial period	Lapsed/ Forfeited during the financial period	As at end of the financial period
<i>To certain employees and a director</i>					
Number of Award Shares	-	70,418,300	28,258,700	-	42,159,600

There were no treasury shares and subsidiary holdings held by the Company as at 31 March 2022 and 31 March 2023.

20. Share-based payment reserve

Share-based payment reserve represents the equity-settled performance shares granted to directors and employees pursuant to the Plan, and equity-settled shares granted to third party individuals as consideration in lieu of fees for their services rendered and in part as performance-based incentives for future performance of such service.

The share-based payment expense is recorded over the requisite service period, which is the vesting period.

The carrying amounts of share-based payment reserve and the movements during the period are set out below:

	Group and Company S\$'000
Balance as at 1 January 2023	-
Vesting of Awards	424
Employee share-based payment – equity settled recognised in profit or loss	(424)
Balance as at 31 March 2023	-

21. Net asset value per share

	Group		Company	
	As at 31/3/23	As at 31/12/22	As at 31/3/23	As at 31/12/22
Net (liability) value (S\$'000)	(996)	(1,688)	(1,038)	(1,719)
Number of Shares ('000)	559,127	493,368	559,127	493,368
Net (liability) value per share (cents)	(0.18)	(0.34)	(0.19)	(0.35)

22. Related party transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

23. Segment information

For management purposes and resource allocation, the Group is organised into business operating units based on reports reviewed by the management team that are used to make strategic decisions.

(a) **Cancer**

The cancer segment involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the cancer field.

(b) **Infectious diseases**

The infectious diseases segment involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field.

(c) **Laboratory services**

The laboratory services segment involves the business, operation and provision of laboratory services to customers.

(d) **Corporate segment**

The corporate segment involves the corporate functions in supporting the operations of the entire Group.

Segment profit represents the profit earned by each segment without allocation of other gains and losses, distribution and selling expenses, administrative expenses, finance income and finance cost. This is the measure reported to the chief operating decision makers for the purposes of resource allocation and performance assessment.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segment:

1Q FY2023	Cancer S\$'000	Infectious diseases S\$'000	Laboratory services S\$'000	Corporate segment S\$'000	Total S\$'000
Revenue:					
External customers	108	-	976	-	1,084
Inter-segment	-	-	-	-	-
Total revenue	108	-	976	-	1,084
Segment results:					
Other income	-	-	-	15	15
Employee benefits expense	(13)	(11)	(234)	(220)	(478)
Depreciation expense	(5)	-	(74)	(18)	(97)
Amortisation expense	-	-	-	-	-
Research and development expense	(2)	-	-	-	(2)
Other expenses	(2)	-	(220)	(103)	(325)
Finance costs	-	-	(1)	(35)	(36)
Segment profit / (loss) before tax	7	(17)	28	(361)	(343)
Income tax credit	-	-	-	-	-
Segment profit / (loss) after tax	7	(17)	28	(361)	(343)
Assets:					
Additions to non-current assets	-	-	-	-	-

1Q FY2022	Cancer S\$'000	Infectious diseases S\$'000	Laboratory services S\$'000	Corporate segment S\$'000	Total S\$'000
Revenue:					
External customers	62	334	68	-	464
Inter-segment	-	-	-	-	-
Total revenue	62	334	68	-	464
Segment results:					
Other income	-	-	-	123	123
Employee benefits expense	(30)	(19)	(150)	(430)	(629)
Depreciation expense	(106)	-	(72)	(42)	(220)
Amortisation expense	(21)	-	(83)	-	(104)
Research and development expense	(42)	(57)	-	-	(99)
Other expenses	(31)	(28)	(147)	(144)	(350)
Finance costs	-	-	(2)	(44)	(46)
Segment loss before tax	(138)	(117)	(443)	(515)	(1,213)
Income tax credit	-	-	14	-	14
Segment loss after tax	(138)	(117)	(429)	(515)	(1,199)
Assets:					
Additions to non-current assets	21	-	10	3	34

Geographical information

Revenue information based on the geographical location of customers are as follows:

	Cancer		Infectious diseases		Laboratory services	
	1Q FY2023 S\$'000	1Q FY2022 S\$'000	1Q FY2023 S\$'000	1Q FY2022 S\$'000	1Q FY2023 S\$'000	1Q FY2022 S\$'000
Segment revenue						
Singapore	-	6	-	288	975	38
Japan	1	28	-	-	-	-
China	-	1	-	-	-	-
Europe	3	-	-	-	-	2
Hong Kong	19	27	-	-	-	-
Taiwan	-	-	-	-	-	21
Philippines	-	-	-	-	1	4
Indonesia	-	-	-	46	-	-
Thailand	85	-	-	-	-	-
Others	-	-	-	-	-	3
	108	62	-	334	976	68

Information about major customers

Revenue from three (1Q FY2022: three) major customers amounted to approximately S\$0.84 million in 1Q FY2023 (1Q FY2022: S\$0.32 million), arising from sales from the cancer and laboratory services segments (1Q FY2022: Infectious diseases segment).

F. OTHER INFORMATION REQUIRED UNDER THE CATALIST RULES

PART I - INFORMATION REQUIRED FOR QUARTERLY, HALF-YEAR AND FULL YEAR ANNOUNCEMENTS

- 1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Please refer to Section A – Interim consolidated statements of profit or loss and other comprehensive income of this announcement.

- 1(a)(ii) Notes to statement of comprehensive income**

Please refer to Notes 4 to 9 under Section E - Selected notes to the financial statements of this announcement.

- 1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

Please refer to Section B - Statements of financial position of this announcement.

- 1(b)(ii) Aggregate amount of group's borrowings and debt securities.**

Please refer to Note 16 under Section E - Selected notes to the financial statements of this announcement.

- 1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Please refer to Section C - Consolidated statements of cash flows of this announcement.

- 1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial period.**

Please refer to Section D - Statements of changes in equity of this announcement.

- 1(d)(ii) Details of any changes in the Company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any,**

against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Please refer to Note 19 under Section E - Selected notes to the financial statements of this announcement.

1(d)(iii) Total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

Please refer to Note 19 under Section E - Selected notes to the financial statements of this announcement.

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable.

2 Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The figures have not been audited or reviewed by the auditors of the Company.

3 Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).

Not applicable.

- 3A Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:**
(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.
This is not required for any audit issue that is a material uncertainty relating to going concern.

The Company's previous independent auditor, Ernst & Young LLP, had issued a disclaimer of opinion (the "**Disclaimer of Opinion**") in their independent auditor's report dated 10 April 2023 on the audited consolidated financial statements of the Group and the Company for FY2022. The basis for the Disclaimer of Opinion is in relation to (i) the use of the Group's going concern assumption and (ii) the impairment assessment of the Group's plant and equipment, right-of-use assets, intangible assets and goodwill (collectively, "**long-lived assets**"), and the Company's investments in, and other receivable due from, a wholly-owned subsidiary or the Company, Biomedics Laboratory Pte Ltd ("**BML**").

(i) Use of the Group's going concern assumption

To improve the financial health and working capital position of the Group, the Company has completed the Rights Issue in December 2022, raising gross proceeds of approximately S\$5.70 million, before deduction of expenses of approximately S\$0.22 million that was capitalised against the share capital of the Company. The Company also improved the liquidity and working capital position of the Group through the Partial Settlement Deed pursuant to which approximately S\$0.61 million of the Deferred Consideration was settled by way of the issuance of the Consideration Shares to CBSA. As disclosed under Note 2 under Section E - Selected notes to the financial statements of this announcement, management has prepared the Group's and the Company's financial statements for 1Q FY2023 on the basis that the Group and the Company will be able to carry on as a going concern for at least twelve months from the end of 1Q FY2023 based on factors disclosed in that note.

In the event the going concern assumption is no longer appropriate, the financial effects of adjustments to the carrying amounts, and the current and non-current classification of the Group's and Company's assets and liabilities as at 31 March 2023 could be material and pervasive and the Company is unable to determine the extent of the adjustments that may be required.

(ii) Impairment assessment of the Group's plant and equipment, right-of-use assets, intangible assets and goodwill, and the Company's investments in, and other receivable due from, a wholly-owned subsidiary or the Company.

In FY2022, the Group had recorded total impairment losses of approximately S\$4.04 million on the long-lived assets. As at 31 March 2023, the carrying amounts of the long-lived assets was less than S\$0.20 million and management has assessed and concluded that no further impairment losses was required on the long-lived assets.

In FY2022, the Company recorded an impairment loss of approximately S\$3.57 million on its investment in BML, reducing the carrying amount on its investment in BML to nil.

In FY2022, the Company recorded an ECL allowance of approximately S\$2.12 million against the receivable from BML. As at 31 March 2023, the carrying amount of receivable from BML was approximately S\$0.63 million and management has assessed and concluded that no further impairment was required as at 31 March 2023.

Please refer to Notes 2.2, 11, 12, 13 and 14 under Section E - Selected notes to the financial statements of this announcement for further details.

The Board confirms that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

4 Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Please refer to Note 2.1 under Section E - Selected notes to the financial statements of this announcement.

5 If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Please refer to Note 2.1 under Section E - Selected notes to the financial statements of this announcement.

6 Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

Please refer to Note 10 under Section E - Selected notes to the financial statements of this announcement.

7 Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares, excluding treasury shares of the issuer at the end of the (a) current period reported on and (b) immediately preceding financial year.

Please refer to Note 21 under Section E - Selected notes to the financial statements of this announcement.

- 8 **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:**
- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
 - (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

REVIEW OF THE GROUP'S PERFORMANCE

Revenue

Revenue increased by 133.6% or S\$0.62 million, from S\$0.46 million in 1Q FY2022 to S\$1.08 million in 1Q FY2023, due mainly to an increase in revenue from rendering of laboratory services from S\$0.07 million in 1Q FY2022 to S\$0.98 million in 1Q FY2023. The significant increase in revenue from rendering of laboratory services was due to an increase in PCR test services as we provide PCR test services on a 24/7 basis and demand arising from the increase in the number of travelers from the People's Republic of China.

Revenue from the sales of our ClearCell® FX1 system, our CTChip® FR1 biochip and other related services and consumables increased from S\$0.06 million in 1Q FY2022 to S\$0.11 million in 1Q FY2023.

The increase in revenue was partially offset by a decrease in sales of our COVID-19 related products which amounted to nil in 1Q FY2023, as compared to S\$0.33 million in 1Q FY2022, arising from a growing supply of antigen and antibody test kits which led to a highly competitive market under the constraints of intense price competition.

Other income

Other income decreased by S\$0.11 million or 87.8%, from S\$0.12 million in 1Q FY2022 to S\$0.02 million in 1Q FY2023, due mainly to a decrease in foreign exchange gain of S\$0.11 million.

Changes in inventories

We recorded an increase of S\$0.15 million in the closing balance of our inventories in 1Q FY2023, as compared to a decrease of S\$0.08 million in 1Q FY2022. The fluctuations in the balance of our inventories were due mainly to the timing of purchase and sale of inventories.

Purchases

Our purchases increased by S\$0.39 million or 144.8%, from S\$0.27 million in 1Q FY2022 to S\$0.66 million in 1Q FY2023, in line with the increase in revenue from rendering of laboratory services during the financial period.

Employee benefits expense

Employee benefits expense decreased by S\$0.15 million or 24.0%, from S\$0.63 million in 1Q FY2022 to S\$0.48 million in 1Q FY2023, due mainly to the reversal of a provision of S\$0.10 million made for share awards granted under the Biolidics Performance Share Plan.

Depreciation expense

Depreciation expense decreased by S\$0.12 million or 55.9% from S\$0.22 million in 1Q FY2022 to S\$0.10 million in 1Q FY2023 due to assets being fully depreciated in FY2022.

Amortisation expense

Amortisation expense decreased by S\$0.10 million or 100.0% in 1Q FY2023 due to intangible assets being fully impaired in FY2022.

Research and development ("R&D") expense

R&D expense decreased by S\$0.10 million or 98.0% due mainly to the reduction in R&D activities during the financial period.

Other expenses

Other expenses remained relatively unchanged at S\$0.33 million and S\$0.35 million in 1Q FY2023 and 1Q FY2022 respectively.

Finance costs

Finance expenses remained relatively unchanged at S\$0.04 million and S\$0.05 million in 1Q FY2023 and 1Q FY2022 respectively.

Income tax credit

Income tax credit pertains to the reversal of deferred tax liabilities arising from the CAP Accreditation of Biomedics Laboratory Pte. Ltd.. There was no income tax credit recognised in 1Q FY2023 as the deferred tax liabilities was fully reversed in FY2022 arising from fair valuation of the intangible assets.

Loss for the period

As a result of the foregoing, loss for the period decreased by S\$0.86 million or 71.4%, from S\$1.20 million in 1Q FY2022 to S\$0.34 million in 1Q FY2023.

REVIEW OF THE GROUP'S FINANCIAL POSITION

Non-current assets

The Group's non-current assets remained relatively unchanged at S\$0.14 million as at 31 March 2023, as compared to S\$0.17 million as at 31 December 2022.

Current assets

The Group's current assets decreased by 21.2% or S\$1.25 million, from S\$5.92 million as at 31 December 2022 to S\$4.67 million as at 31 March 2023. This was due mainly to a decrease in (i) cash and cash equivalents of S\$1.20 million; (ii) trade receivables of S\$0.10 million (iii) prepayments of S\$0.01 million; and (iv) other receivables of S\$0.11 million, partially offset by an increase in inventories of S\$0.16 million.

Current liabilities

The Group's current liabilities decreased by 28.1% or S\$1.69 million, from S\$6.01 million as at 31 December 2022 to S\$4.32 million as at 31 March 2023. This was due mainly to a decrease in (i) deferred consideration of S\$1.13 million; (ii) other payables of S\$0.59 million; and (iii) contract liabilities of S\$0.10 million, partially offset by an increase in (i) current portion of lease liabilities of S\$0.01 million; and (ii) current portion of borrowings of S\$0.01 million.

As at 31 March 2023, the Group's net current assets was S\$0.35 million and the Group was in a net equity deficit position of S\$1.00 million.

Non-current liabilities

The Group's non-current liabilities decreased by 15.9% or S\$0.28 million, from S\$1.77 million as at 31 December 2022 to S\$1.49 million as at 31 March 2023. This was due mainly to a decrease in (i) borrowings of S\$0.27 million comprising the non-current portion of working capital bank loans; and (ii) non-current portion of lease liabilities of S\$0.01 million.

REVIEW OF THE GROUP'S CASH FLOW STATEMENT

Operating cash outflow before movements in working capital amounted to S\$0.20 million in 1Q FY2023. Net cash used for working capital amounted to S\$0.09 million due mainly to (i) an increase in inventories of S\$0.16 million; (ii) a decrease in other payables of S\$0.16 million; and (iii) a decrease in contract liabilities of S\$0.10 million, partially offset by (i) a decrease in trade receivables of S\$0.10 million; (ii) a decrease in prepayments of S\$0.01 million; (iii) a decrease in other receivables of S\$0.11 million; and (iv) an increase in trade payables of S\$0.11 million. As a result, net cash used in operating activities was S\$0.32 million in 1Q FY2023.

Net cash used in investing activities in 1Q FY2023 amounted to S\$0.55 million. This was due mainly to partial payment of the Deferred Consideration of S\$0.55 million in cash.

Net cash used in financing activities in 1Q FY2023 amounted to S\$0.33 million. This was due mainly to the payment of S\$0.26 million and S\$0.07 million of the principal portions of borrowings and lease liabilities respectively in 1Q FY2023.

As a result of the above, there was a net decrease in cash and cash equivalents by S\$1.20 million, from S\$5.03 million as at 31 December 2022 to S\$3.83 million as at 31 March 2023.

9 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable. No forecast or prospect statement has been previously disclosed to shareholders.

10 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

In FY2022, the Group's commenced COVID-19 PCR testing as one of its service offerings which it will continue to offer in the current financial year ending 31 December 2023.

As set out under Note 8 under Section F – Other information required under the Catalist Rules of this announcement, revenue from rendering of COVID-19 PCR test services accounted for more than 90% of the Group's revenue in 1Q FY2023. However, due to the rapidly evolving nature of the COVID-19 pandemic, the demand for COVID-19 PCR tests continues to be exposed to various uncertainties and challenges such as the emergence of competing and newer technologies, product regulatory changes, and changes in travel policies and restrictions as well as emergence of new competitors providing similar PCR test services. As such, there is no certainty that such revenue from rendering of COVID-19 PCR test services can be maintained at the level achieved in 1Q FY2023. The Group will continue to explore opportunities to generate revenue from its laboratory services business segment by pivoting into other test services, subject to the requisite time to develop and obtain the relevant approvals required to undertake such new test services.

The COVID-19 pandemic has resulted in significant delays to the Group's development of its Cancer business segment. The Group will continue to review its product and service offerings in order to keep pace with the uncertainties and challenges and ensure that the Group's business remains relevant and sustainable. The Group will also continue to explore merger and acquisition opportunities to improve its financial performance.

To manage the challenges and uncertainties, including rising cost of conducting business, the Group has since June 2022 implemented cost rationalisation measures such as streamlining of its manpower structure, scaling down of the R&D activities for its Cancer business segment, and reducing the engagement of external service providers.

To strengthen its financial position, the Group has completed the Rights Issue in December 2022 and may explore opportunities to monetise its assets, including its intellectual properties which is encapsulated in the ClearCell® FX1 system as well as fund raising opportunities, including undertaking equity issuances in the future.

The Company will continue to provide timely updates to its shareholders should there be any material development affecting the Group's business and operations.

11 Dividend

(a) Whether an interim (final) ordinary dividend has been declared (recommended)

Nil

(b) (i) Amount per share

Nil

(ii) Previous corresponding period

Nil

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be shared).

Not applicable.

(d) Date the dividend is payable

Not applicable.

(e) Date on which Registrable Transfers received by the Company (up to 5pm) will be registered before entitlements to the dividend are determined

Not applicable.

12 If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared by the Company as the Group had incurred losses in 1Q FY2023.

13 If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group has obtained a general mandate from shareholders for interested person transactions, which had expired following the conclusion of the Company's annual general meeting held on 28 April 2023 ("**IPT Mandate**").

There were no interested person transactions (excluding transactions less than S\$100,000 and transactions conducted under the IPT Mandate pursuant to Rule 920 of the Catalist Rules) and interested person transactions conducted under the IPT Mandate pursuant to Rule 920 (excluding transactions less than S\$100,000) during 1Q FY2023.

14 Negative confirmation by the board pursuant to Rule 705(5)

To the best of the knowledge of the board of directors of the Company ("**Board**"), nothing has come to the attention of the Board which may render the unaudited financial results for 1Q FY2023 of the Group and the Company to be false or misleading in any material aspect.

15 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company confirms that it has procured the undertakings from all of its directors and executive officers as required under Rule 720(1) of Catalyst Rules.

16 Use of proceeds from the Rights Issue

Pursuant to the issuance of 227,916,205 Rights Shares on 2 December 2022, the Company received net proceeds from the Rights Issue of approximately S\$5.42 million. As at the date of this announcement, the net proceeds from the Rights Issue have been utilised as follows:

(S\$'000)	Amount allocated (as disclosed in the results of Rights Issue announcement dated 2 December 2022)	Amount utilised as at the date of this announcement	Balance
Working capital requirements of the Group ⁽¹⁾	2,905	2,863	42
Mergers and acquisitions activities	2,515	-	2,515
Total	5,420	2,863	2,557

Note:

- (1) The amount utilised for working capital requirements of the Group as at the date of this announcement was mainly for operating expenses of the Group.

17 Disclosure pursuant to Rule 706A of the Catalist Rules

There was no acquisition or sale of shares by the Company during 1Q FY2023 which requires disclosure pursuant to Rule 706A of the Catalist Rules.

ON BEHALF OF THE BOARD

Song Tang Yih
Executive Director and Chief Executive Officer

28 April 2023